HighCom FY26 slides: revenue rebounds 73% in H2 amid recovery

HighCom’s FY26 revenue fell to A$29.8M (from A$48.1M) but management highlighted a sharp rebound with H2 revenue at A$18.9M vs A$10.9M in H1 (+73%). Losses widened, with negative FY26 EBITDA of A$6.8M (vs A$0.2M loss in FY25), though the H2 EBITDA loss of A$1.4M was within guidance (A$1.2M–A$1.6M). The company strengthened liquidity via an A$7.8M capital raise, ending FY26 with A$9.7M cash (up from A$5.8M) and A$7.3M total available liquidity, and cited an A$1.2B sales pipeline plus an A$8.9M follow-on MyDefence order for counter-drone systems.

Analysis

This is more a financing-and-conversion story than a clean earnings recovery. The capital raise and debt maturity extension remove near-term solvency pressure, but the business still needs several quarters of execution to outrun burn; in small-cap defense, that can support the share price for a while, yet it only becomes durable if operating cash flow inflects before the next working-capital cycle turns. The key near-term tell is whether FY27 bookings translate into cash without another equity tap.

The more interesting second-order angle is competitive positioning: the integrated armor-plus-counter-drone bundle may improve tender win-rates versus pure-play armor vendors, but it also pushes HCM into a channel where larger integrators and better-capitalized defense contractors can undercut on service, financing, and delivery certainty. That means the apparent pipeline is less valuable than it looks unless conversion rates improve; in defense, “scoped opportunity” often compresses sharply when procurement priorities shift or budget windows move.

Contrarian view: the market may be overreacting to the second-half rebound and underweighting how much of it was timing, inventory liquidation, and normalizing procurement rather than a true step-change in end demand. The structural upside from XTclave and counter-drone is real, but the valuation case is still hostage to margins, not just revenue, because the current mix remains dominated by lower-differentiation armor. Falsify the bear case if H1 FY27 shows sustained order flow, positive EBITDA, and cash holding above the current run-rate without further dilution.

Key Decisions for Investors

• Do not chase HCM on the post-results bounce; treat it as a watchlist name until FY27 quarterly data shows bookings converting into positive operating cash flow. Falsify the cautionary stance if cash stays above A$7m and EBITDA loss narrows materially quarter-over-quarter.
• Relative-value idea: long DroneShield (DRO.AX) vs. HCM if you want exposure to the counter-drone budget cycle. DRO has better scale and liquidity, while HCM still carries higher dilution and execution risk; this pair benefits if the category re-rates but capital markets remain selective.
• If forced into HCM, size it as a speculative event-driven trade only and use a hard stop below the recent support band around A$0.091. The setup is asymmetric only if one of the large defense opportunities converts into binding revenue within 1-2 quarters.
• Watch for a second financing or working-capital squeeze over the next 3-6 months; if cash trends back toward A$6m and there is no follow-on contract conversion, reduce exposure aggressively. That would indicate the recovery is mostly timing noise, not a durable inflection.